(0)
Preliminary Data from Single-Ascending Dose Cohorts Expected Later this Year Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that the company has initiated patient dosing in the multiple ascending dose (MAD) portion of its ACeD study (Assessment of KAN-101 in Celiac Disease), a Phase 1 clinical trial evaluating KAN-101 for the treatment of individuals with celiac disease. Initiation of the MAD cohort enrollment follows completion of the first two single-ascending dose (SAD) cohorts in the trial, with the third SAD cohort actively dosing patients.
KAN-101, Anokion s lead antigen-specific drug product candidate, aims to re-educate immune cells to not respond to gluten antigens. The ACeD study is a randomized, double-blind, placebo-controlled Phase 1 trial that will enroll a total of up to 40 patients with celiac disease who are on a gluten free diet. The study is composed of two parts. In
Anokion Appoints Deborah Geraghty, Ph D , as President and Chief Executive Officer morningstar.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from morningstar.com Daily Mail and Mail on Sunday newspapers.
Anokion SA: Anokion Appoints Deborah Geraghty, Ph.D., as President and Chief Executive Officer
Raj Manchanda, Ph.D., Promoted to Chief Development Officer Anokion SA, a Swiss biotechnology company focused on treating autoimmune disease by restoring normal immune tolerance, today announced that Deborah Geraghty, Ph.D., has been promoted from chief operating officer to the role of president and chief executive officer, reporting to the Board of Directors, following John Hohneker, M.D. s, retirement from the company. In addition, Raj Manchanda, Ph.D., has been promoted to chief development officer (CDO) after serving as Anokion s chief technical operations officer since 2019.